A subpopulation of cancer cells, termed cancer stem cells (CSCs), has stemness properties, such as self-renewal and differentiation, which drive cancer recurrence and tumor resistance. CSCs possess enhanced protection capabilities to maintain reduced intracellular levels of reactive oxygen species (ROS) compared with nonstem-like cancer cells. This study investigated whether reductive stress could regulate self-renewal activity in breast CSCs.
Results:
We found that manifestation of stemness in breast cancer stem-like cells was associated with an elevated production of reduced glutathione (GSH) maintained by upregulation of glutamate cysteine ligase catalytic subunit (GCLC) and consequently, lowered ROS levels. This was accompanied by upregulation of phospho-AMP-activated protein kinase, FoxO3a, and Bmi-1. Notably, expression of nuclear factor erythroid-derived 2-like 2 (Nrf2) protein was substantially increased in cells undergoing sphere formation. We noticed that expression of Bmi-1 was inhibited after introduction of Nrf2 short interfering RNA into MCF-7 mammosphere cells. Silencing of Nrf2 expression suppressed the xenograft growth of subcutaneously or orthotopically injected human breast cancer cells.
Innovation:
Association between Nrf2 and self-renewal signaling in CSCs has been reported, but the underlying molecular mechanism remains largely unresolved. This study demonstrates the Nrf2-mediated signaling pathway in maintenance of reductive stress in breast CSCs.
Conclusion:
Nrf2 overactivation in breast CSCs upregulates GCLC expression and consequently enhances GSH biosynthesis with concurrent reduction in intracellular ROS accumulation, thereby provoking the reductive stress. The consequent upregulation of nuclear FoxO3a and its binding to the promoter of the gene encoding Bmi-1 account for the self-renewal activity of breast cancer stem-like cells and their growth in a xenograft mouse model.
Get full access to this article
View all access options for this article.
References
1.
AbadE, Garcia-MayeaY, MirC, SebastianD, ZorzanoA, PotesilD, ZdrahalZ, LyakhovichA, and LleonartME. Common metabolic pathways implicated in resistance to chemotherapy point to a key mitochondrial role in breast cancer. Mol Cell Proteomics, 18: 231–244, 2019.
2.
AcciliD and ArdenKC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell, 117: 421–426, 2004.
3.
AoiW, OgayaY, TakamiM, KonishiT, SauchiY, ParkEY, WadaS, SatoK, and HigashiA. Glutathione supplementation suppresses muscle fatigue induced by prolonged exercise via improved aerobic metabolism. J Int Soc Sports Nutr, 12: 7, 2015.
4.
AquilanoK, BaldelliS, and CirioloMR. Glutathione: new roles in redox signaling for an old antioxidant. Front Pharmacol, 5: 196, 2014.
5.
ChenC, LiuY, LiuY, and ZhengP. The axis of mTOR-mitochondria-ROS and stemness of the hematopoietic stem cells. Cell Cycle, 8: 1158–1160, 2009.
6.
ChengX and O'NeillHC. Oncogenesis and cancer stem cells: current opinions and future directions. J Cell Mol Med, 13: 4377–4384, 2009.
7.
ChiacchieraF and SimoneC. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle, 9: 1091–1096, 2010.
8.
DeanM, FojoT, and BatesS. Tumour stem cells and drug resistance. Nat Rev Cancer, 5: 275–284, 2005.
9.
DiehnM, ChoRW, LoboNA, KaliskyT, DorieMJ, KulpAN, QianD, LamJS, AillesLE, WongM, JoshuaB, KaplanMJ, WapnirI, DirbasFM, SomloG, GarberoglioC, PazB, ShenJ, LauSK, QuakeSR, BrownJM, WeissmanIL, and ClarkeMF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature, 458: 780–783, 2009.
10.
DongK, WuM, LiuX, HuangY, ZhangD, WangY, YanLJ, and ShiD. Glutaredoxins concomitant with optimal ROS activate AMPK through S-glutathionylation to improve glucose metabolism in type 2 diabetes. Free Radic Biol Med, 101: 334–347, 2016.
11.
FreedmanJH, CirioloMR, and PeisachJ. The role of glutathione in copper metabolism and toxicity. J Biol Chem, 264: 5598–5605, 1989.
GorriniC, HarrisIS, and MakTW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov, 12: 931–947, 2013.
14.
HoKK, McGuireVA, KooCY, MuirKW, de OlanoN, MaifoshieE, KellyDJ, McGovernUB, MonteiroLJ, GomesAR, NebredaAR, CampbellDG, ArthurJS, and LamEW. Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J Biol Chem, 287: 1545–1555, 2012.
15.
HuJ, LiG, ZhangP, ZhuangX, and HuG. A CD44v(+) subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity. Cell Death Dis, 8: e2679, 2017.
16.
JangYY and SharkisSJ. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood, 110: 3056–3063, 2007.
17.
JiaY, ChenJ, ZhuH, JiaZH, and CuiMH. Aberrantly elevated redox sensing factor Nrf2 promotes cancer stem cell survival via enhanced transcriptional regulation of ABCG2 and Bcl-2/Bmi-1 genes. Oncol Rep, 34: 2296–2304, 2015.
18.
KakehashiA, IshiiN, SugiharaE, GiM, SayaH, and WanibuchiH. CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma. Cancer Sci, 107: 609–618, 2016.
19.
KimJH, YoonSY, KimCN, JooJH, MoonSK, ChoeIS, ChoeYK, and KimJW. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett, 203: 217–224, 2004.
20.
KippAP, DeubelS, ArnerESJ, and JohanssonK. Time- and cell-resolved dynamics of redox-sensitive Nrf2, HIF and NF-κB activities in 3D spheroids enriched for cancer stem cells. Redox Biol, 12: 403–409, 2017.
21.
KlotzLO, Sanchez-RamosC, Prieto-ArroyoI, UrbanekP, SteinbrennerH, and MonsalveM. Redox regulation of FoxO transcription factors. Redox Biol, 6: 51–72, 2015.
22.
LuH, SamantaD, XiangL, ZhangH, HuH, ChenI, BullenJW, and SemenzaGL. Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci U S A, 112: E4600–E4609, 2015.
23.
LukacsRU, MemarzadehS, WuH, and WitteON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell, 7: 682–693, 2010.
24.
MarkovicJ, BorrasC, OrtegaA, SastreJ, VinaJ, and PallardoFV. Glutathione is recruited into the nucleus in early phases of cell proliferation. J Biol Chem, 282: 20416–20424, 2007.
25.
MarkovicJ, Garcia-GimenezJL, GimenoA, VinaJ, and PallardoFV. Role of glutathione in cell nucleus. Free Radic Res, 44: 721–733, 2010.
26.
McMahonM, ItohK, YamamotoM, ChanasSA, HendersonCJ, McLellanLI, WolfCR, CavinC, and HayesJD. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res, 61: 3299–3307, 2001.
27.
MiyamotoK, ArakiKY, NakaK, AraiF, TakuboK, YamazakiS, MatsuokaS, MiyamotoT, ItoK, OhmuraM, ChenC, HosokawaK, NakauchiH, NakayamaK, NakayamaKI, HaradaM, MotoyamaN, SudaT, and HiraoA. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell, 1: 101–112, 2007.
28.
MizunoT, SuzukiN, MakinoH, FuruiT, MoriiE, AokiH, KunisadaT, YanoM, KujiS, HirashimaY, ArakawaA, NishioS, UshijimaK, ItoK, ItaniY, and MorishigeK. Cancer stem-like cells of ovarian clear cell carcinoma are enriched in the ALDH-high population associated with an accelerated scavenging system in reactive oxygen species. Gynecol Oncol, 137: 299–305, 2015.
29.
NguyenT, NioiP, and PickettCB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem, 284: 13291–13295, 2009.
30.
OgasawaraMA and ZhangH. Redox regulation and its emerging roles in stem cells and stem-like cancer cells. Antioxid Redox Signal, 11: 1107–1122, 2009.
31.
ParanjapeAN, BalajiSA, MandalT, KrushikEV, NagarajP, MukherjeeG, and RangarajanA. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer, 14: 785, 2014.
PearsonT, KabayoT, NgR, ChamberlainJ, McArdleA, and JacksonMJ. Skeletal muscle contractions induce acute changes in cytosolic superoxide, but slower responses in mitochondrial superoxide and cellular hydrogen peroxide. PLoS One, 9: e96378, 2014.
34.
Poillet-PerezL, DespouyG, Delage-MourrouxR, and Boyer-GuittautM. Interplay between ROS and autophagy in cancer cells, from tumor initiation to cancer therapy. Redox Biol, 4: 184–192, 2015.
35.
ProctorE, WaghrayM, LeeCJ, HeidtDG, YalamanchiliM, LiC, BednarF, and SimeoneDM. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One, 8: e55820, 2013.
36.
RyooIG, ChoiBH, KuSK, and KwakMK. High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: implications for cancer stem cell resistance. Redox Biol, 17: 246–258, 2018.
37.
RyooIG, ChoiBH, and KwakMK. Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget, 6: 8167–8184, 2015.
38.
RyooIG, KimG, ChoiBH, LeeSH, and KwakMK. Involvement of NRF2 signaling in doxorubicin resistance of cancer stem cell-enriched colonospheres. Biomol Ther, 24: 482–488, 2016.
39.
ShiX, ZhangY, ZhengJ, and PanJ. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal, 16: 1215–1228, 2012.
40.
SilvaJ, GarciaV, GarciaJM, PenaC, DominguezG, DiazR, LorenzoY, HurtadoA, SanchezA, and BonillaF. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res, 9: R55, 2007.
41.
SinghA and SettlemanJ. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29: 4741–4751, 2010.
42.
SkvortsovaI, DebbageP, KumarV, and SkvortsovS. Radiation resistance: cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Semin Cancer Biol, 35: 39–44, 2015.
43.
SyuJP, ChiJT, and KungHN. Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget, 7: 14659–14672, 2016.
44.
TaguchiK, MotohashiH, and YamamotoM. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells, 16: 123–140, 2011.
45.
TothovaZ, KolliparaR, HuntlyBJ, LeeBH, CastrillonDH, CullenDE, McDowellEP, Lazo-KallanianS, WilliamsIR, SearsC, ArmstrongSA, PassegueE, DePinhoRA, and GillilandDG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell, 128: 325–339, 2007.
46.
YangB, MaYF, and LiuY. Elevated expression of Nrf-2 and ABCG2 involved in multi-drug resistance of lung cancer SP cells. Drug Res (Stuttg), 65: 526–531, 2015.
47.
ZhangC, WangHJ, BaoQC, WangL, GuoTK, ChenWL, XuLL, ZhouHS, BianJL, YangYR, SunHP, XuXL, and YouQD. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget, 7: 73593–73606, 2016.
48.
ZhaoY, HuX, LiuY, DongS, WenZ, HeW, ZhangS, HuangQ, and ShiM. ROS signaling under metabolic stress: cross-talk between AMPK and AKT pathway. Mol Cancer, 16: 79, 2017.
49.
ZhuJ, WangH, SunQ, JiX, ZhuL, CongZ, ZhouY, LiuH, and ZhouM. Nrf2 is required to maintain the self-renewal of glioma stem cells. BMC Cancer, 13: 380, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
